Data presented at International Carbohydrate Symposium
EAGAN, MN — August 2, 2012 — Biothera researchers enhanced the biological activity of a fungal beta glucan by altering its molecular structure, confirming previous research demonstrating the link between branching and functionality, according to data presented last week at the International Carbohydrate Symposium in Madrid.
For the study, carbohydrate chemists at Biothera used scleroglucan, a fungal beta 1,3 glucan that is highly branched with single glucose molecules. When the branching was reduced from 30% to 12%, the average molecular weight increased, indicating the formation of complex higher ordered structures. The single helical structures aggregated into triple helical structures that significantly increased their biological activity.
“By changing the molecular structure, we were able to transform a relatively inactive fungal beta glucan into one with greater biological activity,” said Dan Conners, president of Biothera’s Pharmaceutical Group. “This research highlights Biothera’s expertise in carbohydrate chemistry and our unmatched knowledge of beta glucan biotechnology.”
“The data confirms our earlier studies demonstrating that structure matters and that not all beta glucans are created equal,” said Rich Mueller, president of Biothera’s Healthcare Group. “Ingredient or product claims must be supported by research with that specific ingredient and strain and not borrowed research.”
The poster presented at the symposium was entitled, “Modification of a Beta Glucan Affects Aggregation Behavior and Biological Activity.” Authors: Magee, A.S.; Langeslay, R.R.; Will, P.M.; Elmasry, N.A.; Danielson, M.E. Abstract.
Previous Biothera research showing that subtle differences in the molecular structure of various beta 1,3/1,6 glucans can significantly affect their ability to enhance innate immune system responses was presented at the National Cancer Institute.
About Biothera, the immune health company
Biothera is a biotechnology company dedicated to improving immune health. The company is commercializing its unique technology platform through two business groups. Biothera’s Pharmaceutical Group is conducting multiple clinical trials for the development of a drug that mobilizes the innate immune system to fight most types of cancer. The company’s Healthcare Group is a leading provider of natural immune health ingredients for functional foods, beverages, dietary supplements, cosmetics and animal nutrition.
Biothera, the Immune Health Company